Efficacy and safety of BLV monotherapy for chronic hepatitis delta: posttreatment results through 48 weeks after the end of treatment from an interim analysis of a randomised Phase 3 study MYR301

被引：0

作者：

Aleman, S. ^{[1
]}

Brunetto, M. ^{[2
,3
]}

Blank, A. ^{[4
]}

Andreone, P. ^{[5
]}

Bogomolov, P. ^{[6
]}

Chulanov, V. ^{[7
]}

Mamonova, N. ^{[8
]}

Geyvandova, N. ^{[9
]}

Morozov, V. ^{[10
]}

Sagalova, O. ^{[11
]}

Stepanova, T. ^{[12
]}

Chee, G. M. ^{[13
]}

Mercier, R. C. ^{[13
]}

Lichtman, A. ^{[13
]}

Manuilov, D. ^{[13
]}

Arterburn, S. ^{[13
]}

Lau, A. H. ^{[13
]}

Osinusi, A. ^{[13
]}

Christian-Cox, Flo. ^{[13
]}

Duff, F. ^{[13
]}

zur Wiesch, J. Schulze ^{[14
]}

Cornberg, M. ^{[15
]}

Zeuzem, S. ^{[16
]}

Wedemeyer, H. ^{[15
]}

Lampertico, P. ^{[17
,18
]}

机构：

[1] Karolinska Inst, Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden

[2] Univ Hosp Pisa, Reference Ctr Tuscany Reg Chron Liver Dis & Canc, Hepatol Unit, Pisa, Italy

[3] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy

[4] Heidelberg Univ, Heidelberg Univ Hosp, Med Fac Heidelberg, Internal Med Dept Clin Pharmacol & Pharmacoepidemi, Heidelberg, Germany

[5] Univ Modena & Reggio Emilia, Baggiovara Hosp, Internal Med, Modena, Italy

[6] MF Vladimirsky Moscow Reg Res & Clin Inst, Moscow, Russia

[7] Sechenov Univ, Moscow, Russia

[8] Minist Hlth Russian Federat, FSBI Natl Res Med Ctr Phthisiopulmonol & Infect Di, Moscow, Russia

[9] Stavropol Reg Hosp, Stavropol, Russia

[10] LLC Med Co Hepatolog, Samara, Russia

[11] South Ural State Med Univ, Chelyabinsk, Russia

[12] LLC Clin Modern Med, Moscow, Russia

[13] Gilead Sci Inc, Foster City, CA USA

[14] Univ Hosp Hamburg Eppendorf, Med Microbiol, Hamburg, Germany

[15] Hannover Med Sch, Clin Gastroenterol Hepatol Infect Dis & Endocrinol, Hannover, Germany

[16] Goethe Univ, Univ Hosp, Dept Nucl Med, Frankfurt, Germany

[17] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy

[18] Univ Milan, CRC A M&A Migliavacca Ctr Liver Dis, Dept Pathophysiol & Transplantat, Milan, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2025年 / 57卷

关键词：

D O I：

10.1016/j.dld.2025.01.109

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P-69

引用

页数：2

共 47 条

[41] Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment Results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)
Raz, Itamar
Fonseca, Vivian
Kipnes, Mark
Durrwell, Laurence
Hoekstra, John
Boldrin, Mark
Balena, Raffaella
DIABETES CARE, 2012, 35 (03) : 485 - 487
[42] Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta
Etzion, Ohad
Hamid, Saeed Sadiq
Asselah, Tarik
Gherlan, George Sebastian
Turcanu, Adela
Petrivna, Tsarynna
Weissfeld, Lisa
Choong, Ingrid
Hislop, Colin
Apelian, David
Buti, Maria
Gheorghe, Liana
Iliescu, Elena Laura
Voronkova, Natalia
Barsukova, Natalia
Aleman, Soo
Feld, Jordan J.
Reau, Nancy S.
Brunetto, Maurizia
Lampertico, Pietro
Heller, Theo
Koh, Chris
Yurdaydin, Cihan
Glenn, Jeffrey
JOURNAL OF HEPATOLOGY, 2023, 78 : S10 - S10
[43] Study Design, Baseline and Open-Label Results from XTEND-CIU: A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab through 48 Weeks in Patients with Chronic Idiopathic Urticaria
Casale, Thomas B.
Scarupa, Mark D.
Holden, Michael
Trzaskoma, Benjamin L.
Antonova, Evgeniya
Win, Patrick H.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB271 - AB271
[44] RG-101 IN COMBINATION WITH 4 WEEKS OF ORAL DIRECT ACTING ANTIVIRAL THERAPY ACHIEVES HIGH VIROLOGIC RESPONSE RATES IN TREATMENT NAIVE GENOTYPE 1 AND 4 CHRONIC HEPATITIS C PATIENTS: INTERIM RESULTS FROM A RANDOMISED, MULTI-CENTER, PHASE 2 STUDY
Horvath, G.
Papatheodoridis, G.
Fabri, M.
Makara, M.
Grint, P.
Huang, M.
Blem, J.
Lombardi, E.
JOURNAL OF HEPATOLOGY, 2016, 64 : S159 - S159
[45] EFFICACY AND SAFETY OF COMBINATION TREATMENT WITH siRNA JNJ-73763989 AND CAPSID ASSEMBLY MODULATOR JNJ-56136379 (BERSACAPAVIR) IN HBEAG NEGATIVE VIROLOGICALLY SUPPRESSED CHRONIC HEPATITIS B PATIENTS: FOLLOW-UP WEEK 48 END OF STUDY RESULTS FROM REEF-2
Agarwal, Kosh
Buti, Maria, Sr.
Van Boemmel, Florian
Lampertico, Pietro
Janczewska, Ewa
Bourliere, Marc
Vanwolleghem, Thomas
Lenz, Oliver
Verbinnen, Thierry
Kakuda, Thomas N.
Mayer, Cristiana
Jezorwski, John
Muenz, Daniel
Beumont, Maria
Kalmeijer, Ronald
Biermer, Michael
Lonjon-Domanec, Isabelle
HEPATOLOGY, 2023, 77 (05) : E127 - E128
[46] Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Followup from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population
Mauro, Michael
Minami, Yosuke
Hochhaus, Andreas
Lomaia, Elza
Voloshin, Sergei
Turkina, Anna
Kim, Dong-Wook
Apperley, Jane F.
Cortes, Jorge
Abdo, Andre N. R.
Fogliatto, Laura Maria
Kim, Dennis Dong Hwan
le Coutre, Philipp
Saussele, Susanne
Annunziata, Mario
Hughes, Timothy P.
Chaudhri, Naeem A.
Chee, Lynette C. Y.
Gutierrez, Valentin Garcia
Sasaki, Koji
Freitas, Carla Maria Boquimpani De Moura
Kapoor, Shruti
Espurz, Noemi
Dhamal, Vishal
Rea, Delphine
BLOOD, 2023, 142
[47] A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results
Lampertico, Pietro
Buti, Maria
Ramji, Alnoor
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Yoon, Seung Kew
Kao, Jia-Horng
Chen, Chi-Yi
Tam, Edward
Khalili, Mandana
Bae, Ho
Ma, Xiaoli
Tak, Won Young
Flaherty, John F.
Gaggar, Anuj
Suri, Vithika
Tan, Susanna
Liu, Yang
Wu, George
Subramanian, Mani
Hann, Hie-Won
Agarwal, Kosh
Lim, Young-Suk
Chan, Henry
JOURNAL OF HEPATOLOGY, 2020, 73 : S67 - S68

← 1 2 3 4 5 →